University of California San Francisco
Give to UCSF
UCSF scientists found a way to predict Alzheimer’s disease up to seven years before symptoms appear by analyzing patient records with machine learning. Conditions that most influenced prediction of Alzheimer’s were high cholesterol and, for women, osteoporosis.
Medication abortion can be delivered safely and effectively through telemedicine, according to new research that comes as the U.S. Supreme Court is about to hear a case that could severely restrict access to one of the two pills that are used to induce abortions.
Cancer immunotherapy is hindered by the fact that engineered immune cells often get worn out and depleted before they've killed a tumor. A UCSF team has identified mutations that give cancerous lymphoma T-cells their superpower and transfer those genes into engineered, therapeutic immune cells.
In a first, scientists at UCSF and Stanford identified genetic variants that predict whether a patient is likely to respond to treatment for preterm birth. Screening for mutations could allow doctors to target medications to those most likely to benefit. No medication is currently available in the U.S. to treat preterm birth.
Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug.
Fruit bats have a genetic system that controls blood sugar without fail. Learning from that system can help us make better insulin- or sugar-sensing therapies for human patients.
The Danaher-IGI Beacon for CRISPR Cures center will use genome editing to address potentially hundreds of diseases, including rare genetic disorders that have no cure, to ensure treatments can be developed and brought to patients more quickly and efficiently.
Many physicians are unfamiliar with how the Food and Drug Administration’s (FDA) regulates new drugs and medical devices, and they may be under the impression that the data supporting these approvals
UC San Francisco’s Thomas G. Martin, MD, a leading expert in blood cancers, has received a grant of nearly $4.6 million from the California Institute of Regenerative Medicine (CIRM) to produce a CAR T
A team of researchers from UC San Francisco has found that Paxlovid did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection.
The new JN.1 COVID-19 variant is now estimated to make up about 20% of cases in the United States. Three UCSF experts offer advice on vaccines, masking, and other ways to protect yourself.
Could AI make nurses’ jobs – and our health care – better? Kay Burke, MBA, RN, who helps UCSF Health improve its digital tools, weighs in.
